Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 283

Sort by

Sort Order Select

Journal Articles

Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects

Blood (2023) 142 (Supplement 1): 2548.

https://doi.org/10.1182/blood-2023-178062

Published: 2023

Journal Articles

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Mike P. Agius, Laura Hevenor, N Connor Payne, Ralph Mazitschek, Hyuk-Soo Seo, Sirano Dhe-Paganon, Jun Qi, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2023-186864

Published: 2023

Journal Articles

Multi-Center Clinical Validation of a Mass Spectrometry Immunoassay for the Diagnosis and Monitoring of Multiple Myeloma and Associated Disorders

Oscar Berlanga, Jane Birtwistle, Syreeta Allen, Gemma Malin, Cristina Simion, Habib El-Khoury, Julia Colchie, Luca Bertamini, Grace Fleming, Erica M. Horowitz, Irene M. Ghobrial, Kaleb B McLendon, John Roback, Andrew S Neish, Sarah K Grewal, Gabriella Lakos

Blood (2023) 142 (Supplement 1): 3667.

https://doi.org/10.1182/blood-2023-189050

Published: 2023

Journal Articles

High-Throughput Plasma Proteomics to Define the Precursor Multiple Myeloma Proteome and Identify Candidate High-Risk Disease Biomarkers of Progression

Blood (2023) 142 (Supplement 1): 334.

https://doi.org/10.1182/blood-2023-189091

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2023-177947

Published: 2023

Journal Articles

Understanding Patient Preferences for Intervention in Individuals with Precursor Multiple Myeloma: The Preference Study

Catherine R. Marinac, Katelyn Downy, Irene M. Ghobrial, Jacqueline Perry, Brittany Fischer-Longden, Timothy R Rebbeck, Elizabeth K. O'Donnell, Omar Nadeem, Brian Egleston

Blood (2023) 142 (Supplement 1): 4775.

https://doi.org/10.1182/blood-2023-190035

Published: 2023

Journal Articles

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Blood (2023) 142 (Supplement 1): 206.

https://doi.org/10.1182/blood-2023-177954

Published: 2023

Journal Articles

Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenstrom's Macroglobulinemia

Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Daniel L. Mallory, Ting Wu, Michelle P. Aranha, Junko Tsuji, Nicholas J Haradhvala, Elizabeth D. Lightbody, Katherine Towle, Laura Hevenor, Nickolas Tsakmaklis, Xiyue Wang, Alexa G Canning, Christine-Ivy Liacos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Steven P Treon, Gady Getz, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2023-186470

Published: 2023

Journal Articles

Genome Sequencing to Discover Drivers of Clonal Expansion in Smoldering Multiple Myeloma

Jean-Baptiste Alberge, Ankit K. Dutta, Elizabeth D. Lightbody, Andrea Poletti, Sofia Wallin, Andrew Dunford, Tim Coorens, Xavi Loinaz, Cody J. Boehner, Nang Kham Su, Laura Hevenor, Katherine Towle, Jacqueline Perry, Kirsten Kübler, Romanos Sklavenitis-Pistofidis, Julian Hess, Chip Stewart, Gad Getz, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2023-184900

Published: 2023

Journal Articles

Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Mechanisms of Disease Dissemination

Blood (2023) 142 (Supplement 1): 872.

https://doi.org/10.1182/blood-2023-189760

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Kelsey Tague, Veronica Romines, Amada Metivier, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2021-149787

Published: 2021

Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Cynthia C. Harrington, Jill N. Burke, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri

Blood (2021) 138 (Supplement 1): 4082.

https://doi.org/10.1182/blood-2021-146342

Published: 2021

Journal Articles

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Amada Metivier, Kelsey Tague, Veronica Romines, Meredith Bertoni, Alexandra Savell, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Clifton C. Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 4782.

https://doi.org/10.1182/blood-2021-148023

Published: 2021

Journal Articles

Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology

Ankit K. Dutta, Elizabeth D. Lightbody, Ziao Lin, Jean-Baptiste Alberge, Romanos Sklavenitis-Pistofidis, Tarek H Mouhieddine, Annie Cowan, Nang K. Su, Cody J. Boehner, Hadley Barr, Steven Gross, Ornkleaw Zepp, Thai Bui, Jared Mayes, Daniel Auclair, Gad Getz, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 78.

https://doi.org/10.1182/blood-2021-150622

Published: 2021

Journal Articles

Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients

Mahshid Rahmat, Kendell Clement, Romanos Sklavenitis-Pistofidis, Rohan Kodgule, Charles Fulco, Jean-Baptiste Alberge, Cody J. Boehner, Michael P. Agius, Elizabeth Morgan Kitzenberg, David Dorfman, Russell J. H. Ryan, Luca Pinello, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 504.

https://doi.org/10.1182/blood-2021-150734

Published: 2021

Journal Articles

Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia

Sabrin Tahri, Tarek H Mouhieddine, Robert A. Redd, Luisa Maria Lampe, Katarina Nillson, Nang Kham Su, Habib El-Khoury, Amin H Nassar, Elio Adib, Govind Bindra, Sarah Abou Alaiwi, Lorenzo Trippa, David P. Steensma, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial, Adam S. Sperling

Blood (2021) 138 (Supplement 1): 2678.

https://doi.org/10.1182/blood-2021-149711

Published: 2021

Journal Articles

Single Cell Characterization of Myeloma and Its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis

Rebecca Boiarsky, Nicholas Haradhvala, Romanos Sklavenitis-Pistofidis, Tarek H Mouhieddine, Jean-Baptiste Alberge, Oksana Zavidij, Danielle Firer, Shankara Anand, Habib El-Khoury, François Aguet, David Sontag, Irene M. Ghobrial, Gad Getz

Blood (2021) 138 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2021-150889

Published: 2021

NARROW

Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Multi-Center Clinical Validation of a Mass Spectrometry Immunoassay for the Diagnosis and Monitoring of Multiple Myeloma and Associated Disorders

High-Throughput Plasma Proteomics to Define the Precursor Multiple Myeloma Proteome and Identify Candidate High-Risk Disease Biomarkers of Progression

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Understanding Patient Preferences for Intervention in Individuals with Precursor Multiple Myeloma: The Preference Study

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenstrom's Macroglobulinemia

Genome Sequencing to Discover Drivers of Clonal Expansion in Smoldering Multiple Myeloma

Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Mechanisms of Disease Dissemination

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology

Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients

Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia

Single Cell Characterization of Myeloma and Its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only